search
Back to results

Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial

Primary Purpose

Cerebrovascular Disorders, Hemiplegia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Robot-Low
Robot-High
Control
Sponsored by
US Department of Veterans Affairs
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cerebrovascular Disorders focused on measuring Rehabilitation, Robotics

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Over 21 years of age, weakness due to a recent stroke or other brain injury, and receiving rehabilitation. Subjects are inpatients at one of the participating VA hospitals. Exclusion Criteria: Unable to follow instructions; medically unstable.

Sites / Locations

  • VA Palo Alto Health Care System
  • VA Greater Los Angeles Healthcare System, West LA
  • Michael E. DeBakey VA Medical Center (152)
  • Central Texas Veterans Health Care System

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Robot-Low

Robot-High

Control

Arm Description

low-dose mechanically-assisted upper limb therapy

high-dose mechanically-assisted upper limb therapy

additional traditional therapy

Outcomes

Primary Outcome Measures

Fugl-Meyer Score Change Immediately Following Study Intervention.
Change in Fugl-Meyer Assessment (FMA) score. The FMA evaluates motor function, sensation, balance, and joint function in hemiplegic patients and provides a cumulative numerical score. It is widely used to evaluate changes in function over time in clinical care and therapeutic trials following stroke. Five domains can be assessed, including motor function (upper and lower limbs); sensory function; balance; joint range of motion; and joint pain. Items within each domain are scored on a 3-point ordinal scale: 0 = cannot perform; 1 = performs partially; and 2 = performs fully. Subscales can be administered without the using the full test. For the upper limb motor function subscale used in this clinical trial, 33 items were evaluated, each rated on a 3-point scale (0-2), then summed for a maximum possible score of 66. A greater increase in the score represents a greater improvement in upper limb motor function.
Fugl-Meyer Score Change at 6 Months
Change in Fugl-Meyer score at 6-months from study enrollment compared to baseline. Maximum score = 66.

Secondary Outcome Measures

Change in FIM Score Immediately Following Study Intervention.
Change in the upper limb portion of the Functional Independence Measure (FIM) was assessed to determine treatment impact on independence in activities of daily living (ADL). The FIM indicates the level of disability based on how much assistance is required for an individual to carry out ADL. It can be used to assess13 motor and 5 cognitive tasks, each rated on a 7 point ordinal scale (0 = total assistance or complete dependence; 7 = complete independence in the task). Tasks include For this study, a subset of 9 tasks involving the upper limbs was used (maximum score = 63). A greater change represents a greater improvement in independence carrying out tasks requiring functional use of the upper limbs.
Change in FIM Score at 6-months
Change in FIM score at 6-months from study enrollment compared to baseline. Maximum score = 63 .

Full Information

First Posted
September 14, 2005
Last Updated
January 3, 2014
Sponsor
US Department of Veterans Affairs
search

1. Study Identification

Unique Protocol Identification Number
NCT00223808
Brief Title
Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial
Official Title
Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
January 2002 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
US Department of Veterans Affairs

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the effectiveness of a lower-dose and higher-dose therapy program for persons recovering from a recent stroke using mechanically-assisted upper limb movement with a device called MIME. A control group receives additional occupational therapy without the use of MIME.
Detailed Description
This study continues our investigation of the optimal timing, intensity, and duration of robot-assisted training to improve motor performance in patients with hemiplegia following stroke. These hypotheses will be tested: 1) subjects receiving robot-assisted upper limb therapy with MIME in the initial phase of recovery from stroke experience greater functional gains than a control group receiving additional conventional therapy of equal intensity and duration, 2) robot-assisted therapy results in a dose-dependent response, and 3) robot-assisted therapy promotes greater control of movement, greater recovery of strength, and greater reduction of co-contraction than the control intervention. Research Plan - A multi-site clinical trial is in progress at the Houston VA Medical Center (VAMC), the VA Greater Los Angeles Health Care System (GLAHCS), the VA Palo Alto Rehabilitation Research and Development Center (RR&DC), and the Central Texas Veterans Health Care System (CTVHCS). CTVHCS serves as the coordinating site. The RR&DC provides training and technical assistance for the other sites. Methods - Subjects with hemiparesis due to a stroke are randomly assigned to 3 groups. Group 1 receives 1 hour/day of robot-assisted upper limb therapy in addition to usual physical and occupational therapy. Group 2 receives a total of 2 hours/day of robot-assisted therapy. Group 3 receives 1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot. Outcome measures include assessment of strength, motor control, functional status, and patient satisfaction at intake, discharge, 6 and 12 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebrovascular Disorders, Hemiplegia
Keywords
Rehabilitation, Robotics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
71 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Robot-Low
Arm Type
Experimental
Arm Description
low-dose mechanically-assisted upper limb therapy
Arm Title
Robot-High
Arm Type
Experimental
Arm Description
high-dose mechanically-assisted upper limb therapy
Arm Title
Control
Arm Type
Active Comparator
Arm Description
additional traditional therapy
Intervention Type
Other
Intervention Name(s)
Robot-Low
Intervention Description
1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
Intervention Type
Other
Intervention Name(s)
Robot-High
Intervention Description
2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
Intervention Type
Other
Intervention Name(s)
Control
Intervention Description
1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
Primary Outcome Measure Information:
Title
Fugl-Meyer Score Change Immediately Following Study Intervention.
Description
Change in Fugl-Meyer Assessment (FMA) score. The FMA evaluates motor function, sensation, balance, and joint function in hemiplegic patients and provides a cumulative numerical score. It is widely used to evaluate changes in function over time in clinical care and therapeutic trials following stroke. Five domains can be assessed, including motor function (upper and lower limbs); sensory function; balance; joint range of motion; and joint pain. Items within each domain are scored on a 3-point ordinal scale: 0 = cannot perform; 1 = performs partially; and 2 = performs fully. Subscales can be administered without the using the full test. For the upper limb motor function subscale used in this clinical trial, 33 items were evaluated, each rated on a 3-point scale (0-2), then summed for a maximum possible score of 66. A greater increase in the score represents a greater improvement in upper limb motor function.
Time Frame
After study intervention (on completion of the maximum planned number of sessions for their group or discharge from inpatient rehabilitation, whichever came first) compared to baseline at study enrollment between 7 and 21 days post-stroke.
Title
Fugl-Meyer Score Change at 6 Months
Description
Change in Fugl-Meyer score at 6-months from study enrollment compared to baseline. Maximum score = 66.
Time Frame
FMA at 6 months from study enrollment compared to baseline FMA performed prior to study intervention, which began between 7 and 21 days post-stroke.
Secondary Outcome Measure Information:
Title
Change in FIM Score Immediately Following Study Intervention.
Description
Change in the upper limb portion of the Functional Independence Measure (FIM) was assessed to determine treatment impact on independence in activities of daily living (ADL). The FIM indicates the level of disability based on how much assistance is required for an individual to carry out ADL. It can be used to assess13 motor and 5 cognitive tasks, each rated on a 7 point ordinal scale (0 = total assistance or complete dependence; 7 = complete independence in the task). Tasks include For this study, a subset of 9 tasks involving the upper limbs was used (maximum score = 63). A greater change represents a greater improvement in independence carrying out tasks requiring functional use of the upper limbs.
Time Frame
After study intervention (on completion of the maximum planned number of sessions for each group or discharge from inpatient rehabilitation, whichever came first) compared to baseline at study enrollment between 7 and 21 days post-stroke.
Title
Change in FIM Score at 6-months
Description
Change in FIM score at 6-months from study enrollment compared to baseline. Maximum score = 63 .
Time Frame
Change in FIM score at 6-months from study enrollment compared to baseline FIM prior to study intervention, which began between 7 and 21 days post-stroke.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Over 21 years of age, weakness due to a recent stroke or other brain injury, and receiving rehabilitation. Subjects are inpatients at one of the participating VA hospitals. Exclusion Criteria: Unable to follow instructions; medically unstable.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles Burgar, MD
Organizational Affiliation
Central Texas Veterans Health Care System
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Palo Alto Health Care System
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304-1290
Country
United States
Facility Name
VA Greater Los Angeles Healthcare System, West LA
City
West Los Angeles
State/Province
California
ZIP/Postal Code
90073
Country
United States
Facility Name
Michael E. DeBakey VA Medical Center (152)
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Central Texas Veterans Health Care System
City
Temple
State/Province
Texas
ZIP/Postal Code
76504
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21674393
Citation
Burgar CG, Lum PS, Scremin AM, Garber SL, Van der Loos HF, Kenney D, Shor P. Robot-assisted upper-limb therapy in acute rehabilitation setting following stroke: Department of Veterans Affairs multisite clinical trial. J Rehabil Res Dev. 2011;48(4):445-58. doi: 10.1682/jrrd.2010.04.0062.
Results Reference
result

Learn more about this trial

Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial

We'll reach out to this number within 24 hrs